Pharmacist-Led Care for Older Australians Living With Polypharmacy

Walk into any community pharmacy in Melbourne, Adelaide or suburban Sydney on a Tuesday morning and you will meet an older patient carrying a plastic bag of medicines. The bag usually holds a statin, a blood pressure tablet, metformin, an inhaler, a blister pack from a specialist and something for the knee. It may also hold a bottle of vitamin D, fish oil and a small supermarket box of paracetamol. That collection is the visible edge of polypharmacy, and for most patients it is a normal part of getting older rather than a sign that anything is wrong.

Polypharmacy is commonly defined as the regular use of several medicines, and in clinical practice the threshold that raises most concern is five or more. Australian Institute of Health and Welfare data indicate a substantial share of people aged over 65 years use five or more medicines, with the figure climbing among people who live with diabetes, kidney disease, arthritis, atrial fibrillation and dementia at the same time. These patients are the group most likely to move between three prescribers, three pharmacies and one residential care provider without anyone holding a complete picture.

The consequences are not abstract. Medication-related harm contributes to a meaningful share of preventable hospital admissions in Australia, and the Australian Commission on Safety and Quality in Health Care treats medication safety as a national standard precisely because the burden falls hardest on older adults. Confusion, falls, hypoglycaemia, bleeding and acute kidney injury all cluster in the same people who are already the most frequent users of the Pharmaceutical Benefits Scheme.

Pharmisters hold a position few other health professionals do. The patient does not need a referral, does not need an appointment and does not need a Medicare card to walk in, and the pharmacist sees the whole medication list, including over-the-counter analgesics and complementary medicines that never appear on a hospital discharge summary. That makes community pharmacy the natural setting for pharmacist-led interventions that reduce polypharmacy in older adults with multiple chronic conditions.

What drives medication accumulation in older Australians

Three forces combine to create the problem. The first is appropriate multimorbidity: evidence-based guidelines for type 2 diabetes, heart failure, hypertension and chronic kidney disease each call for several medicines, and a patient with four of those conditions may be on twelve drugs by design. The second is the mismatch between life expectancy and time to benefit, which makes drugs prescribed for primary prevention questionable in some very old patients, particularly statins where the benefit takes years to accrue.

The third force is prescribing cascades and fragmented care. A calcium channel blocker causes ankle swelling, a second drug is added for the swelling, and the swelling itself disappears once the first drug is adjusted. Meanwhile a discharge summary from a private hospital in Melbourne, a repeat from a GP in Ballarat and a psychotropic from a mental health service in Brisbane produce three overlapping lists, none of them complete. The result is a regimen that grew organically rather than being designed.

The harms that show up at the pharmacy counter

Anticholinergic burden is one of the least discussed risks. Many of the medicines handed over without a second thought, including some antihistamines for itch, certain antidepressants, bladder antispasmodics and combination cold and flu preparations, add up to a cumulative anticholinergic load that predicts dry mouth, blurred vision, constipation, urinary retention and delirium. A patient who has never felt unwell can quietly become cognitively slower over two years.

Other risks are more mechanical and more Australian than international guidelines sometimes acknowledge. Over-the-counter paracetamol bought at a discount supermarket can stack with a paracetamol-containing compound analgesic from the pharmacy, pushing a patient past the maximum daily dose without anyone noticing. An NSAID sold for knee pain, taken alongside an ACE inhibitor or ARB and a thiazide, is the classic triple whammy combination that tips a patient into acute kidney injury. Schedule 8 opioids and benzodiazepines remain common sources of falls, and each of these problems is visible in the dispensing record if a pharmacist takes the time to read it as a whole rather than item by item.

Deprescribing is the intervention with the strongest evidence behind it, and it is also the one most patients have never heard of. International tools such as STOPP/START and the Beers criteria are widely applied here, alongside the Australian Drug Ageing and Medication Exclusion (DAME) tool, which was developed locally to suit aged care and primary care settings and flags medicines that are inappropriate at a given age, condition or combination.

Medication reconciliation as the starting point

Reconciliation means building one accurate list of everything a patient takes, comparing it with what is prescribed, and resolving the differences. It sounds administrative, yet it is the single highest-yield step in reducing inappropriate polypharmacy, because most of the excess sits in the categories no prescriber can see.

The community pharmacy is well placed to do it. A patient can be asked to bring the dosette box from the weeknight table, the packets of tablets kept in a kitchen drawer, the creams in the bathroom cabinet and the vitamins from the pantry. The pharmacist then reconciles that haul against the dispensing history from every pharmacy the patient has used and against the medication list in My Health Record. Practices wanting a proven workflow for how to conduct a successful medication reconciliation in a busy community pharmacy can adapt a structured approach to fit counter conversations that run two minutes rather than thirty.

Two Australian details shape the task. Patients routinely use two or three pharmacies, often because a discount chain near home is more convenient than the one near the specialist, so dispensing history must be requested rather than assumed complete. And since 2020 the Therapeutic Goods Administration has capped paracetamol packs at 30 tablets, which means buying for a month is not possible in one transaction, yet the same medicine still circulates informally between family members.

Deprescribing conversations patients will accept

Stopping a medicine that a patient has taken for a decade is a clinical task with a communication task attached. The evidence on withdrawal harm is real for certain classes, so benzodiazepines should be tapered over weeks rather than stopped abruptly, opioids need a plan for the pain that will re-emerge, and an inhaled steroid should not be discontinued without a replacement strategy in place. Deprescribing without a plan simply converts one problem into another.

What works better is shared decision making, framed around the patient's own goals. An 82-year-old in Hobart who values walking to the shops without dizziness has a stronger reason to stop a sedating antihistamine than any lecture about anticholinergic scoring. Pharmacists can support this by bringing the deprescribing criteria, the patient priorities and the prescriber's own concerns onto one page and letting the patient choose the order of change.

Documentation closes the loop. A referral to the GP with a clear rationale, a proposed taper and a request to update the medication list at the next consultation stops the old tablet returning to the shelf at the next repeat. Practices with a Team Care Arrangement can formalise that collaboration, fund ongoing pharmacist input and make deprescribing a shared goal rather than a favour granted once.

Reaching patients at home and beyond the city

Home Medicines Reviews, funded through Medicare after a GP referral, and medication management reviews for residents of aged care homes remain the backbone of pharmacist-led medication care in Australia. They are also the part of the system most in need of local adaptation, because the patients with the heaviest regimens are frequently the ones who live furthest from a hospital and have the least access to a pharmacist face to face.

That describes much of rural and remote Australia. A pharmacist in Dubbo, Toowoomba, Bendigo or a remote Aboriginal medical service in Central Australia may be the only medicines expert a patient will see all year. Telehealth expands reach, but it does not expand the pharmacist's ability to see the loose tablets in the drawer, the fridge items or the creams, so the home visit still carries the value. Culturally safe practice, the trust built through the local Aboriginal health service and the practical reality that medicines are shared across households all need to sit inside the review process rather than outside it.

Community pharmacy programs built around brief, structured consultations show what is achievable when the workflow is designed for the counter. A detailed example of implementing a pharmacist-led smoking cessation program in a rural community pharmacy illustrates the pattern well: define the patient group, book a specific time, use a repeatable clinical protocol, supply the therapy directly and schedule a follow-up call. The same architecture transfers directly to a polypharmacy service, with the consultation expanded to cover the whole regimen rather than one behaviour.

Making the service sustainable in a discount market

Australian community pharmacy operates in an unusual retail environment. Chemist Warehouse, Priceline and Amcal compete with supermarkets that sell paracetamol and ibuprofen at checkout prices, so patients have a legitimate expectation of low prices and hard-won goodwill toward the dispensing counter. A pharmacist-led review that costs the patient time and money will not be taken up, which means the service has to be free at the point of delivery and funded through Medicare item numbers, a Team Care Arrangement or a contract with a local aged care provider.

Workload is the other constraint. Reviews performed without protected time become unpaid goodwill, and the Pharmaceutical Society of Australia and Pharmacy Board guidance make clear that clinical documentation, continuing professional development and quality use of medicines are obligations rather than options. Practices that succeed protect a fixed session each week, train their technicians to prepare the medication list before the patient arrives, and record outcomes so the service can be reviewed with the GP and the aged care facility.

There is a regulatory reason to keep complementary medicines in scope too. The Therapeutic Goods Administration registers listed medicines that may contain ingredients pharmacologically active in ways consumers do not expect, and a pharmacist is often the only person who will ask whether the St John's wort on the shelf interacts with the antidepressant and the anticoagulant in the dosette box.

A practical blueprint for pharmacist-led polypharmacy care

A structured service can be built without new infrastructure, using existing funding and a defined workflow.

  • Offer a free bring-everything brown-bag review appointment, with the dosette box, all packets, creams, vitamins and fridge items requested in advance.
  • Prepare the list before the patient arrives by pulling dispensing history from other pharmacies and comparing it with the medication list in My Health Record.
  • Partner with one local general practice, agree a written referral pathway and a Team Care Arrangement, and review deprescribing proposals together.
  • Target the highest-burden medicines first, including anticholinergics, benzodiazepines, long-term proton pump inhibitors, opioids and duplicate paracetamol or NSAID use.
  • Tap the funding that already exists: Medicare-funded home and medication management reviews, the community pharmacy consultation service, and aged care contracts.
  • Train the whole team on deprescribing criteria such as DAME and STOPP/START, on tapering protocols and on culturally safe engagement.
  • Measure what changes: medicines stopped, doses reduced, falls and hospital admissions avoided, and patient-reported confidence in managing the regimen.

Put one patient on the schedule this week

The quickest way to test this model is to select a handful of patients whose dispensing records show five or more medicines, duplicated paracetamol, a long-term benzodiazepine or an anticholinergic load, and invite them to a booked review with no fee. Bring the criteria, bring the patient priorities and bring the referral letter to the GP, and let the first reviews generate the evidence that justifies protected time and ongoing funding.

Pharmacists working in this space are encouraged to document their protocols and share them with colleagues, because the marginal value of a deprescribing conversation multiplies quickly when the next pharmacist in the pharmacy picks up the same process. The conversation with an older patient about the twelve tablets in the plastic bag is often the first time anyone has asked them to look at the whole picture, and that opportunity is worth the protected hour it takes.